642 related articles for article (PubMed ID: 14615704)
1. [Interest of the use of pindolol in the treatment of depression: review].
Brousse G; Schmitt A; Chereau I; Eschalier A; Dubray C; Llorca PM
Encephale; 2003; 29(4 Pt 1):338-50. PubMed ID: 14615704
[TBL] [Abstract][Full Text] [Related]
2. Pindolol augmentation of antidepressant treatment: recent contributions from brain imaging studies.
Martinez D; Broft A; Laruelle M
Biol Psychiatry; 2000 Oct; 48(8):844-53. PubMed ID: 11063979
[TBL] [Abstract][Full Text] [Related]
3. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius.
Pérez V; Soler J; Puigdemont D; Alvarez E; Artigas F
Arch Gen Psychiatry; 1999 Apr; 56(4):375-9. PubMed ID: 10197835
[TBL] [Abstract][Full Text] [Related]
4. The use of pindolol to potentiate antidepressant medication.
Blier P; Bergeron R
J Clin Psychiatry; 1998; 59 Suppl 5():16-23; discussion 24-5. PubMed ID: 9635544
[TBL] [Abstract][Full Text] [Related]
5. Pindolol and the acceleration of the antidepressant response.
Plenge P; Mellerup ET
J Affect Disord; 2003 Aug; 75(3):285-9. PubMed ID: 12880941
[TBL] [Abstract][Full Text] [Related]
6. Pindolol, a putative 5-hydroxytryptamine(1A) antagonist, does not reverse the inhibition of serotonergic neuronal activity induced by fluoxetine in awake cats: comparison to WAY-100635.
Fornal CA; Martin FJ; Metzler CW; Jacobs BL
J Pharmacol Exp Ther; 1999 Oct; 291(1):220-8. PubMed ID: 10490908
[TBL] [Abstract][Full Text] [Related]
7. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.
Foster RH; Goa KL
CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224
[TBL] [Abstract][Full Text] [Related]
8. Differential occupancy of somatodendritic and postsynaptic 5HT(1A) receptors by pindolol: a dose-occupancy study with [11C]WAY 100635 and positron emission tomography in humans.
Martinez D; Hwang D; Mawlawi O; Slifstein M; Kent J; Simpson N; Parsey RV; Hashimoto T; Huang Y; Shinn A; Van Heertum R; Abi-Dargham A; Caltabiano S; Malizia A; Cowley H; Mann JJ; Laruelle M
Neuropsychopharmacology; 2001 Mar; 24(3):209-29. PubMed ID: 11166513
[TBL] [Abstract][Full Text] [Related]
9. Other Antidepressants.
Schwasinger-Schmidt TE; Macaluso M
Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
[TBL] [Abstract][Full Text] [Related]
10. The augmentation hypothesis for improvement of antidepressant therapy: is pindolol a suitable candidate for testing the ability of 5HT1A receptor antagonists to enhance SSRI efficacy and onset latency?
Kinney GG; Taber MT; Gribkoff VK
Mol Neurobiol; 2000 Jun; 21(3):137-52. PubMed ID: 11379796
[TBL] [Abstract][Full Text] [Related]
11. Pindolol augmentation enhances response outcomes in first depressive episodes.
Portella MJ; de Diego-Adeliño J; Puigdemont D; Pérez-Egea R; Alvarez E; Artigas F; Pérez V
Eur Neuropsychopharmacol; 2009 Jul; 19(7):516-9. PubMed ID: 19419845
[TBL] [Abstract][Full Text] [Related]
12. Selective activation of postsynaptic 5-HT1A receptors induces rapid antidepressant response.
Blier P; Bergeron R; de Montigny C
Neuropsychopharmacology; 1997 May; 16(5):333-8. PubMed ID: 9109104
[TBL] [Abstract][Full Text] [Related]
13. Is the beneficial antidepressant effect of coadministration of pindolol really due to somatodendritic autoreceptor antagonism?
Cremers TI; Wiersma LJ; Bosker FJ; den Boer JA; Westerink BH; Wikström HV
Biol Psychiatry; 2001 Jul; 50(1):13-21. PubMed ID: 11457419
[TBL] [Abstract][Full Text] [Related]
14. Serotonergic autoreceptor blockade in the reduction of antidepressant latency: personality variables and response to paroxetine and pindolol.
Tome MB; Cloninger CR; Watson JP; Isaac MT
J Affect Disord; 1997 Jul; 44(2-3):101-9. PubMed ID: 9241570
[TBL] [Abstract][Full Text] [Related]
15. Paroxetine with pindolol augmentation: a double-blind, randomized, placebo-controlled study in depressed in-patients.
Geretsegger C; Bitterlich W; Stelzig R; Stuppaeck C; Bondy B; Aichhorn W
Eur Neuropsychopharmacol; 2008 Feb; 18(2):141-6. PubMed ID: 18054209
[TBL] [Abstract][Full Text] [Related]
16. Potentiation by (-)Pindolol of the activation of postsynaptic 5-HT(1A) receptors induced by venlafaxine.
Béïque JC; Blier P; de Montigny C; Debonnel G
Neuropsychopharmacology; 2000 Sep; 23(3):294-306. PubMed ID: 10942853
[TBL] [Abstract][Full Text] [Related]
17. The role of 5-HT(1A) and 5-HT(1B/1D) receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: the mechanism of action of (+/-)pindolol.
Dawson LA; Nguyen HQ
Neuropharmacology; 2000 Apr; 39(6):1044-52. PubMed ID: 10727715
[TBL] [Abstract][Full Text] [Related]
18. Effects of (-)-tertatolol, (-)-penbutolol and (+/-)-pindolol in combination with paroxetine on presynaptic 5-HT function: an in vivo microdialysis and electrophysiological study.
Gartside SE; Clifford EM; Cowen PJ; Sharp T
Br J Pharmacol; 1999 May; 127(1):145-52. PubMed ID: 10369467
[TBL] [Abstract][Full Text] [Related]
19. Once-daily high-dose pindolol for SSRI-refractory depression.
Sokolski KN; Conney JC; Brown BJ; DeMet EM
Psychiatry Res; 2004 Feb; 125(2):81-6. PubMed ID: 15006431
[TBL] [Abstract][Full Text] [Related]
20. Somatodendritic action of pindolol to attenuate the paroxetine-induced decrease in serotonin release from the rat ventral hippocampus: a microdialysis study.
Míguez JM; Paz-Valiñas L; Míguez I; Aldegunde M
Naunyn Schmiedebergs Arch Pharmacol; 2002 May; 365(5):378-87. PubMed ID: 12012024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
